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The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy
has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus
chemotherapy were included and clinical response was evaluated according to response evaluation criteria in solid tumours (RECIST).
Tumours were screened for KRAS mutations using first direct sequencing, then two sensitive methods based on SNaPshot and PCR-
ligase chain reaction (LCR) assays. Clinical response was evaluated according to gene mutations using the Fisher exact test. Times to
progression (TTP) were calculated using the Kaplan–Meier method and compared with log-rank test. A KRAS mutation was detected
in 22 out of 59 tumours and, in six cases, was missed by sequencing analysis but detected using the SNaPshot and PCR-LCR assays.
Remarkably, no KRAS mutation was found in the 12 patients with clinical response. KRAS mutation was associated with disease
progression (P¼0.0005) and TTP was significantly decreased in mutated KRAS patients (3 vs 5.5 months, P¼0.015). Our study
confirms that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need
to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.
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Colorectal cancer is one of the most common tumours and a major
cause of cancer death worldwide. The median overall survival of
patients with a metastatic colorectal cancer (MCRC) has increased
from 12 months to approximately 20 months in the past decade
(Douillard et al, 2003; Meyerhardt and Mayer, 2005; Saunders and
Iveson, 2006). This dramatic improvement was mainly due to the
introduction of both active new chemotherapeutic agents and
novel targeted drugs. The rationale of targeted therapies is to
inhibit biological pathways and key molecules involved in tumour
growth and progression. In CRC, the novel therapies that are
currently used target the vascular endothelial growth factor and
epidermal growth factor (EGF) signaling pathways (Kabbinavar
et al, 2003; Hurwitz et al, 2004; Saltz et al, 2004). The variability of
the MCRC clinical response to anti-EGFR agents has highlighted
the urgent need to identify reliable markers with a predictive value
to select the appropriate patients who can benefit from these
treatments. Essential in this context are two recent studies (Moroni
et al, 2005; Lievre et al, 2006) reporting the characterization of
molecular markers predictive of anti-EGFR antibodies sensitivity
in MCRC. The first study, performed in 31 MCRC patients, showed
that an EGFR gene copy number increase was associated with a
clinical response to anti-EGFR agents and that mutation of KRAS,
downstream of EGF signaling, did not correlate with treatment
sensitivity (Moroni et al, 2005). In contrast, the second study
including 30 MCRC patients reported that KRAS mutation was
highly predictive of tumour resistance to cetuximab (Lievre et al,
2006).
The aim of the present study was to determine the clinical
relevance of KRAS mutation detection in MCRC patients treated
with cetuximab.
MATERIALS AND METHODS
Patients
Patients with an MCRC treated with cetuximab (Erbitux
s, Merck,
Lyon, France) between April 2004 and December 2005 and for
whom tumour DNA was available were included. All patients had
previously received at least one chemotherapy regimen for MCRC.
Cetuximab regimen was associated either with irinotecan or with
oxaliplatin. Tumour response was evaluated according to the
response evaluation criteria in solid tumours (Therasse et al,
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s2000). Patient’s tumour response to cetuximab was classified as
complete response (CR), partial response (PR), stable disease (SD)
or progressive disease (PD).
DNA extraction
DNA was extracted from paraffin-embedded tumour tissue
samples using the DNA extraction kits from Takara (Madison,
WI, USA) or Ambion (Huntingdon, Cambridgeshire, UK),
according to the manufacturer’s instructions. Among the 59
patients analysed, DNA was extracted from the primary tumour
in 53 cases and from metastases in the six remaining cases.
Sequencing analysis
KRAS exon 2 was PCR-amplified from tumour DNA using the
following sense and antisense primers: 50-AAGGCCTGCTGAAAA
TGACTG-30 and 50-CAAAGAATGGTCCTGCACCAG-30. After
purification using the gel extraction kit from Qiagen (Courtaboeuf,
France), PCR products were sequenced using the Big Dye V3.1
Terminator Kit (Applied Biosystems, Foster City, CA, USA) and an
ABI Prism 377 or 3100 DNA sequencer (Applied Biosystems).
Considering the presence of non malignant cells in tumour
samples, the presence of an heterozygous KRAS mutation in the
tumour was defined as the appearance of a mutant peak with an
height of at least one-third of that of the wild type. All sequencing
analyses were performed at least twice on two independent PCRs.
SNaPshot multiplex assay
After purification using gel extraction kit, PCR-amplified KRAS
exon 2 was analysed for the presence of KRAS mutations at
nucleotides c.34, c.35, c.37 and c.38, using the ABI PRISM
SNaPshot Multiplex kit (Applied Biosystems, Foster City, CA,
USA) and four primers including at their 50 end, an additional tail
allowing their simultaneous detection. The sequences of the sense
primers allowing the extension at nucleotides c.34, c.35, c.37 and
c.38 were, respectively, 50-AACTTGTGGTAGTTGGAGCT-30,5 0-N10
ACTTGTGGTAGTTGGAGCTG-30,5 0-N20 TTGTGGTAGTTGGAG
CTGGT-30 and 50-N30 TGTGGTAGTTGGAGCTGGTG-30 (N
indicating the additional nucleotides). The multiplex SNaPshot
reaction was performed in a final volume of 10ml, containing one-
fifth of the PCR reaction, 2.5ml of the SNaPshot Multiplex Ready
Reaction Mix, 1ml of sequencing buffer from the Big Dye V3.1
Terminator Kit and SNaPshot primers at a concentration of 0.02–
0.05mM. Cycling conditions were 25 cycles of rapid thermal ramp
to 961C, 961C for 10s; rapid thermal ramp to 501C, 501C for 5s;
and rapid thermal ramp to 601C and 601C for 30s. SNaPshot
products were then treated 1h at 371C with 3U of shrimp alkaline
phosphatase (Amersham Biosciences/GE Healthcare Europe
GmbH, Saclay, France). After heat inactivation of the alkaline
phosphatase 15min at 751C, labelled products were separated
using a 25min run on an ABI Prism 3130 DNA sequencer and data
were analysed using the GeneMapper Analysis Software version 4.0
(Applied Biosystems).
PCR-LCR
KRAS exon 2 was PCR-amplified using the sense primer 50-
AAGGTACTGGTGGAGTATTTGATAGTG-30 and the antisense
primer 50-TGTTGGATCATATTCGTCCACAAAA-30. Ligase chain
reaction (LCR) was then performed, as described by Shi et al
(2004), on PCR-amplified exon 2 of KRAS, after purification using
the Qiagen gel extraction kit. The c.34 nucleotide was explored
using the specific upstream primer 50-AACTTGTGGTAGTTGGA
GATA-30 (c.34 G4A, p.G12S), or 50-ACTTGTGGTAGTTGGAG
ATT-30 (c.34 G4T, p.G12C) and the common downstream primer
50-GTGGCGTAGGCAAGAGTGC-30; the c.35 nucleotide using the
specific upstream primer 50-TTGTGGTAGTTGGAGCTGA-30 (c.35
G4A; p.G12D), or 50-GTTGTGGTAGTTGGAGCTGC-30 (c.35
G4C; p.G12A), or 50-TTGTGGTAGTTGGAGCTGT-30 (c.35G4T;
p.G12V) and the common downstream primer 50-TGGCGTAGGC
AAGAGTGCC-30; the c.38 nucleotide using the specific upstream
primer 50-TGGTAGTTGGAGCTGGTGA-30 (c.38 G4A; p.G13D)
and the downstream primer 50-CGTAGGCAAGAGTGCCTTGAC-30.
Upstream primers contain at their 50 end the M13F additional
sequence (50-ACTGTAAAACGACGGCCAGTGT-30) and down-
stream primers at their 30 end the M13R additional sequence
(50-TGGTCATAGCTGTTTCCTGCA-30). Upstream primers were
50-6FAM labelled and the downstream primers were 50 phosphory-
lated. Ligase chain reaction reactions were performed in a final
volume of 12.5ml containing 2U of Pfu DNA ligase (Stratagene, la
Jolla, CA, USA), and 1.25mM of each primer. After denaturation at
951C for 20s, 40 two-steps cycles of 941C for 10s alternating with
651C for 2min were performed. Ligation products were analysed
on an ABI Prism 3100 DNA sequencer and the Gene Scan V3.7.1
(Applied Biosystems). For each sample analysed, PCR-LCR was
performed twice.
Statistical analysis
Response to treatment according the mutational status was
evaluated using the Fisher exact test. Patients with CR or PR or
SD were considered as patients with controlled disease (CD). A
P-value equal or o0.05 was considered to indicate statistical
significance. The time to progression (TTP) was calculated as
the period from the beginning of treatment to the first
observation of disease progression or to death. The TTP were
estimated using the Kaplan–Meier method and compared with
the log-rank test.
RESULTS
A total of 59 patients were assessed in the present study.
After 3 months of treatment, 31 patients (52.5%) had a CD, 12
patients (20.3%) had a CR or PR (2 and 10 patients, respectively)
and 19 (32.2%) had an SD. The TTP in patients with CD was 6
months, as compared to 3 months, in patients with PD
(Po0.0001).
KRAS mutation and response to treatment with cetuximab
plus chemotherapy
We detected a KRAS mutation by sequencing analysis of DNA
extracted from tumour sample in 16 out of 59 (27%) patients
(Table 1). Among the 16 patients harbouring a somatic KRAS
mutation, 13 had a PD and three had an SD. Remarkably, no KRAS
mutation was found in the 12 patients with CR or PR. Considering
that the genetic heterogeneity of tumours may hamper the
Table 1 KRAS mutations and response status to cetuximab-based
chemotherapy in 59 MCRC patients
Controlled disease
Complete Partial Stable Progressive
response response disease disease
KRAS mutation
Present 0 0 3 (5) 13 (17)
Absent 2 (2) 10 (10) 16 (14) 15 (11)
Numbers in brackets correspond to the corrected numbers of patients when
sequencing analysis was completed by SNaPshot and PCR–LCR assays.
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in a small fraction of tumour cells, we screened the tumours
without detectable KRAS mutations, using two sensitive methods
able to detect specifically KRAS exon 2 mutations. We developed a
multiplex SNaPshot assay based on primer extension able to detect
simultaneously in a single tube the different KRAS mutations and a
fluorescent PCR-LCR assay. These two analyses were performed
in 11 out of 12 CR/PR patients, in 15 out of 16 patients with SD and
in the 15 PD patients, in whom direct sequencing from tumour
DNA had revealed no mutation. Five additional KRAS mutations
were detected by both methods (Figure 1) and one mutation was
detected only by PCR-LCR assay. These six additional mutations
were found in two SD and four PD patients (Table 1). SNaPshot
and PCR-LCR assays confirmed the absence of KRAS mutations in
the CR/PR patients. In this series of 59 MCRC, sequencing analysis
completed by SNaPshot multiplex and PCR-LCR assays led,
therefore, to the detection of a KRAS mutation in 22 samples
(37%). The presence of KRAS mutation was in this series
significantly associated with PD (P¼0.0005). The predictive value
of KRAS mutation for PD could be estimated to 77.2%, and the
sensitivity and specificity of KRAS mutation for progression to
treatment (CD vs PD) to 60.7 and 83.8%, respectively. The TTP was
significantly decreased in patients harbouring KRAS mutation as
compared to those without detectable mutation (3 vs 5.5 months,
P¼0.015).
DISCUSSION
This study performed on 59 MCRC patients confirms that the
presence of KRAS mutation in tumour is highly predictive of a
non-response to treatment based on cetuximab plus chemo-
therapy, as shown previously in a series of 30 patients (Lievre
et al, 2006). It is important to highlight that, in our series, the
proportions of CR/PR, SD and PD patients were 20.3, 32.2 and
47.5%, respectively, and this distribution is similar to that reported
in the randomised cetuximab trial (Cunningham et al, 2004). The
relationship between KRAS status and sensitivity to anti-EGFR
monoclonal antibodies had not been found previously by Moroni
et al (2005) in a series of 31 patients. This discrepancy might
probably be explained, at least in part, by the limited number of
patients in these latter series. Direct sequencing allowed us to
detect a KRAS mutation in 16 out of 59 patients (27%) with MCRC,
and among the 43 patients without detectable KRAS mutations,
15 presented a PD. We hypothesized that we missed some KRAS
mutations by direct sequencing of tumour DNA, since malignant
tumours are genetically heterogeneous. Furthermore, it is im-
portant to highlight that our study was based on paraffin-
embedded tumours from which it is more difficult to obtain
high-quality DNA. Using two independent sensitive methods,
respectively, based on SNaPshot and PCR-LCR assays specifically
designed to detect KRAS mutation, we detected additional
mutations in two patients with SD, four with PD but none in 11
with CR/PR. This demonstrates the need to use highly sensitive
molecular techniques to ensure detection in tumours of mutations
conferring resistance to treatments. Considering the heterogeneity
of tumour cells, sampling tissue is particularly important. We
determined using SnaPshot assay the KRAS status in two to three
different areas of three tumours including two with KRAS
mutation. These analyses showed that the results did not differ
according to the site of the analysis. The absence of KRAS
mutation in 11 out of 28 patients with PD in our series is probably
explained by the fact that KRAS mutation is not the only genetic
alteration conferring resistance to anti-EGFR antibodies. Indeed
somatic alterations hitting other downstream effectors of the EGFR
transduction cascade, such as RAF, MEK or ERK, may have a
similar effect.
In conclusion, these results should prompt further studies on
larger MCRC series to definitely establish the clinical relevance
of KRAS mutation detection in anti-EGFR antibodies based on
chemotherapy. They also highlight the need to use sensitive
molecular methods to detect mutations conferring resistance and
the two assays presented in this study should facilitate the
detection of KRAS mutations in CRC, on a routine basis. A major
criticism that should be made to all studies on predictive markers
of clinical response to anti-EGFR agents in MCRC, including ours,
is that the clinical response is evaluated on the metastatic disease
whereas the presence of the molecular marker is assessed from the
primary tumour. In the present study we had the opportunity to
compare the KRAS mutational status between primary tumour and
metastases in five patients whom samples were available. In these
five patients, SnaPshot assay had indicated that a KRAS mutation
was present in one case and absent in the remaining five cases. For
these five patients, analysis of the corresponding metastatic site
showed that the KRAS mutation status was identical between the
primary tumour and metastases. Considering the genetic evolution
of metastases compared to primary tumour, we think nevertheless
that it will be important in the future to screen directly metastases
for the presence of alterations conferring either sensitivity or
resistance to these targeted therapies.
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Figure 1 Detection by SNaPShot and PCR-LCR assays of KRAS
mutations not detected by direct sequencing. Direct sequencing of KRAS
exon 2 from control DNA and tumour 12292. The black arrow indicates
the nucleotide c.35 (A). SNaPShot detection of the c.35G4T (p.G12V)
mutation in tumour 12292. Each peak corresponds to a specific extended
primer. The red arrows indicates the peak specific of the c.35G4T
mutation (B). PCR-LCR analysis of tumour 12292, using a dye-labelled
primer specific for the mutant c.35G4C (p.G12A) or c.35G4T (p.G12V)
KRAS allele. The arrow indicates the peak specific of the c.35G4T
mutation (C). Note that the c.35G4T mutation detected by both the
SNaPShot and PCR-LCR assays cannot be clearly detected by sequencing
analysis alone.
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